Polyamine  ||| S:0 E:10 ||| JJ
inhibitors  ||| S:10 E:21 ||| NN
for  ||| S:21 E:25 ||| IN
treatment  ||| S:25 E:35 ||| NN
of  ||| S:35 E:38 ||| IN
feline  ||| S:38 E:45 ||| JJ
oral  ||| S:45 E:50 ||| JJ
squamous  ||| S:50 E:59 ||| JJ
cell  ||| S:59 E:64 ||| NN
carcinoma ||| S:64 E:73 ||| NNS
:  ||| S:73 E:75 ||| :
a  ||| S:75 E:77 ||| DT
proof-of-concept  ||| S:77 E:94 ||| JJ
study  ||| S:94 E:100 ||| NN
This  ||| S:100 E:105 ||| DT
study  ||| S:105 E:111 ||| NN
assessed  ||| S:111 E:120 ||| VBD
proof-of-concept  ||| S:120 E:137 ||| JJ
for  ||| S:137 E:141 ||| IN
use  ||| S:141 E:145 ||| NN
of  ||| S:145 E:148 ||| IN
polyamine  ||| S:148 E:158 ||| FW
inhibitor  ||| S:158 E:168 ||| FW
2-diluoromethylornithine  ||| S:168 E:193 ||| FW
( ||| S:193 E:194 ||| -LRB-
DFMO ||| S:194 E:198 ||| NNP
)  ||| S:198 E:200 ||| -RRB-
as  ||| S:200 E:203 ||| IN
a  ||| S:203 E:205 ||| DT
treatment  ||| S:205 E:215 ||| NN
for  ||| S:215 E:219 ||| IN
oral  ||| S:219 E:224 ||| JJ
squamous  ||| S:224 E:233 ||| JJ
cell  ||| S:233 E:238 ||| NN
carcinoma  ||| S:238 E:248 ||| NNS
( ||| S:248 E:249 ||| -LRB-
SCC ||| S:249 E:252 ||| NNP
)  ||| S:252 E:254 ||| -RRB-
in  ||| S:254 E:257 ||| IN
client-owned  ||| S:257 E:270 ||| JJ
cats ||| S:270 E:274 ||| NNS
.  ||| S:274 E:276 ||| .
Polyamine  ||| S:276 E:286 ||| JJ
levels  ||| S:286 E:293 ||| NNS
in  ||| S:293 E:296 ||| IN
tumor  ||| S:296 E:302 ||| NN
tissue  ||| S:302 E:309 ||| NN
and  ||| S:309 E:313 ||| CC
normal  ||| S:313 E:320 ||| JJ
oral  ||| S:320 E:325 ||| JJ
mucosa  ||| S:325 E:332 ||| NN
were  ||| S:332 E:337 ||| VBD
quantified  ||| S:337 E:348 ||| VBN
before  ||| S:348 E:355 ||| IN
and  ||| S:355 E:359 ||| CC
after  ||| S:359 E:365 ||| IN
treatment ||| S:365 E:374 ||| NN
.  ||| S:374 E:376 ||| .
DFMO  ||| S:376 E:381 ||| NNP
was  ||| S:381 E:385 ||| VBD
administered  ||| S:385 E:398 ||| VBN
orally  ||| S:398 E:405 ||| VBN
to  ||| S:405 E:408 ||| TO
14  ||| S:408 E:411 ||| CD
client-owned  ||| S:411 E:424 ||| JJ
cats  ||| S:424 E:429 ||| NNS
with  ||| S:429 E:434 ||| IN
histologically  ||| S:434 E:449 ||| NN
confirmed  ||| S:449 E:459 ||| VBD
oral  ||| S:459 E:464 ||| JJ
SCC ||| S:464 E:467 ||| NNP
.  ||| S:467 E:469 ||| .
Patients  ||| S:469 E:478 ||| NNS
were  ||| S:478 E:483 ||| VBD
monitored  ||| S:483 E:493 ||| VBN
for  ||| S:493 E:497 ||| IN
gastrointestinal ||| S:497 E:513 ||| NN
,  ||| S:513 E:515 ||| ,
dermatologic ||| S:515 E:527 ||| NN
,  ||| S:527 E:529 ||| ,
auditory ||| S:529 E:537 ||| NN
,  ||| S:537 E:539 ||| ,
hematological ||| S:539 E:552 ||| NN
,  ||| S:552 E:554 ||| ,
and  ||| S:554 E:558 ||| CC
biochemical  ||| S:558 E:570 ||| JJ
abnormalities ||| S:570 E:583 ||| NN
.  ||| S:583 E:585 ||| .
Total  ||| S:585 E:591 ||| JJ
polyamine  ||| S:591 E:601 ||| JJ
levels  ||| S:601 E:608 ||| NNS
in  ||| S:608 E:611 ||| IN
tumor  ||| S:611 E:617 ||| NN
tissue  ||| S:617 E:624 ||| NN
decreased  ||| S:624 E:634 ||| VBD
after  ||| S:634 E:640 ||| IN
treatment ||| S:640 E:649 ||| NN
,  ||| S:649 E:651 ||| ,
as  ||| S:651 E:654 ||| RB
did  ||| S:654 E:658 ||| VBD
the  ||| S:658 E:662 ||| DT
specific  ||| S:662 E:671 ||| JJ
polyamine  ||| S:671 E:681 ||| JJ
putrescine  ||| S:681 E:692 ||| NN
in  ||| S:692 E:695 ||| IN
both  ||| S:695 E:700 ||| DT
tumor  ||| S:700 E:706 ||| NN
tissue  ||| S:706 E:713 ||| NN
and  ||| S:713 E:717 ||| CC
normal  ||| S:717 E:724 ||| JJ
mucosa ||| S:724 E:730 ||| NN
.  ||| S:730 E:732 ||| .
Ototoxicity  ||| S:732 E:744 ||| NNP
was  ||| S:744 E:748 ||| VBD
observed  ||| S:748 E:757 ||| VBN
in  ||| S:757 E:760 ||| IN
5  ||| S:760 E:762 ||| CD
of  ||| S:762 E:765 ||| IN
6  ||| S:765 E:767 ||| CD
cats  ||| S:767 E:772 ||| NNS
receiving  ||| S:772 E:782 ||| VBG
pre-  ||| S:782 E:787 ||| JJ
and  ||| S:787 E:791 ||| CC
post-treatment  ||| S:791 E:806 ||| JJ
brainstem  ||| S:806 E:816 ||| NNS
auditory  ||| S:816 E:825 ||| VBP
evoked  ||| S:825 E:832 ||| JJ
potential  ||| S:832 E:842 ||| JJ
tests ||| S:842 E:847 ||| NNS
.  ||| S:847 E:849 ||| .
Subclinical  ||| S:849 E:861 ||| JJ
thrombocytopenia  ||| S:861 E:878 ||| NN
was  ||| S:878 E:882 ||| VBD
observed  ||| S:882 E:891 ||| VBN
in  ||| S:891 E:894 ||| IN
6  ||| S:894 E:896 ||| CD
of  ||| S:896 E:899 ||| IN
14  ||| S:899 E:902 ||| CD
cats ||| S:902 E:906 ||| NNS
.  ||| S:906 E:908 ||| .
One  ||| S:908 E:912 ||| CD
cat  ||| S:912 E:916 ||| NNS
showed  ||| S:916 E:923 ||| VBD
mild  ||| S:923 E:928 ||| JJ
post-anesthetic  ||| S:928 E:944 ||| JJ
tremors  ||| S:944 E:952 ||| NNS
that  ||| S:952 E:957 ||| IN
resolved  ||| S:957 E:966 ||| VBN
without  ||| S:966 E:974 ||| IN
treatment ||| S:974 E:983 ||| NN
.  ||| S:983 E:985 ||| .
Oral  ||| S:985 E:990 ||| JJ
administration  ||| S:990 E:1005 ||| NN
of  ||| S:1005 E:1008 ||| IN
DFMO  ||| S:1008 E:1013 ||| NNP
at  ||| S:1013 E:1016 ||| IN
doses  ||| S:1016 E:1022 ||| NNS
used  ||| S:1022 E:1027 ||| VBN
in  ||| S:1027 E:1030 ||| IN
this  ||| S:1030 E:1035 ||| DT
study  ||| S:1035 E:1041 ||| NN
resulted  ||| S:1041 E:1050 ||| VBD
in  ||| S:1050 E:1053 ||| IN
significantly  ||| S:1053 E:1067 ||| RB
decreased  ||| S:1067 E:1077 ||| VBN
tumor  ||| S:1077 E:1083 ||| NN
polyamine  ||| S:1083 E:1093 ||| NN
levels  ||| S:1093 E:1100 ||| NNS
without  ||| S:1100 E:1108 ||| IN
life-threatening  ||| S:1108 E:1125 ||| JJ
clinical  ||| S:1125 E:1134 ||| JJ
or  ||| S:1134 E:1137 ||| CC
hematological  ||| S:1137 E:1151 ||| JJ
toxicities ||| S:1151 E:1161 ||| NN
.  ||| S:1161 E:1163 ||| .
Further  ||| S:1163 E:1171 ||| JJ
studies  ||| S:1171 E:1179 ||| NNS
are  ||| S:1179 E:1183 ||| VBP
warranted  ||| S:1183 E:1193 ||| VBN
to  ||| S:1193 E:1196 ||| TO
explore  ||| S:1196 E:1204 ||| VB
pathophysiology  ||| S:1204 E:1220 ||| VBN
of  ||| S:1220 E:1223 ||| IN
polyamine  ||| S:1223 E:1233 ||| JJ
biochemistry  ||| S:1233 E:1246 ||| NN
and  ||| S:1246 E:1250 ||| CC
use  ||| S:1250 E:1254 ||| NN
of  ||| S:1254 E:1257 ||| IN
polyamine  ||| S:1257 E:1267 ||| JJ
inhibitors  ||| S:1267 E:1278 ||| NN
in  ||| S:1278 E:1281 ||| IN
treatment  ||| S:1281 E:1291 ||| NN
of  ||| S:1291 E:1294 ||| IN
cats  ||| S:1294 E:1299 ||| NNS
with  ||| S:1299 E:1304 ||| IN
oral  ||| S:1304 E:1309 ||| JJ
SCC ||| S:1309 E:1312 ||| NNP
.  ||| S:1312 E:1314 ||| .
